Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
39
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings summarySecond quarter of the fiscal year ending March 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit¥-795 million
Ordinary income¥-801 million
Net income¥-802 million
Selling, general and administrative expenses¥101 million
Full-year earnings forecast
Operating Costs
¥1,330 million
Research and Development Expenses
¥1,070 million
General and administrative expenses
¥260 million
Operating profit
¥-1,330 million
Ordinary income
¥-1,340 million
Net income for the current fiscal year
¥-1,350 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Operating Costs60%
Research and Development Expenses65%
General and administrative expenses39%
Operating profit60%
Ordinary income60%
Net income for the current fiscal year59%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Overall, performance was generally in line with expectationsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Operating Costs△¥36 million
- Research and Development Expenses−¥3 million
- General and administrative expenses-¥32 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The plan does not currently factor in business revenue, taking into account the uncertainty surrounding the timing of out-licensing negotiations and development progressNew initiatives
- Preparing for discussions with the US FDA toward an NDA filing for DFP-10917 monotherapy
- Presenting 2 presentations on clinical development data for DFP-10917 at the ASH 2026 Annual Meeting
- Pursuing out-licensing negotiations and joint development with overseas pharmaceutical companies, focusing on pipelines under development
Key KPIsA metric the company considers important as a management benchmark.
- Number of development pipeline candidates6 Projects
- Number of pipelines in clinical trials5 Projects
- Number of accepted presentations at the ASH 2026 Annual Meeting2 Title
- Number of sites for the Phase 3 clinical trial of DFP-14323Approximately 30
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings summary |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Operating profit | ¥-795 million |
| Ordinary income | ¥-801 million |
| Net income | ¥-802 million |
| Selling, general and administrative expenses | ¥101 million |
| Full-year earnings forecast | Business revenue Not disclosed / Operating Costs ¥1,330 million / Research and Development Expenses ¥1,070 million / General and administrative expenses ¥260 million / Operating profit ¥-1,330 million / Ordinary income ¥-1,340 million / Net income for the current fiscal year ¥-1,350 million |
| Progress against full-year forecast | Operating Costs 60% / Research and Development Expenses 65% / General and administrative expenses 39% / Operating profit 60% / Ordinary income 60% / Net income for the current fiscal year 59% |
| Self-assessment against the plan | Overall, performance was generally in line with expectations |
| Breakdown of Factors Affecting the Change | Factors Operating Costs / Amount △¥36 million, Factors Research and Development Expenses / Amount −¥3 million, Factors General and administrative expenses / Amount -¥32 million |
| Key KPIs | Indicator name Number of development pipeline candidates / Value 6 Projects / Year on year against the same period last year Not disclosed, Indicator name Number of pipelines in clinical trials / Value 5 Projects / Year on year against the same period last year Not disclosed, Indicator name Number of accepted presentations at the ASH 2026 Annual Meeting / Value 2 Title / Year on year against the same period last year Not disclosed, Indicator name Number of sites for the Phase 3 clinical trial of DFP-14323 / Value Approximately 30 / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | The plan does not currently factor in business revenue, taking into account the uncertainty surrounding the timing of out-licensing negotiations and development progress |
| New initiatives | Preparing for discussions with the US FDA toward an NDA filing for DFP-10917 monotherapy, Presenting 2 presentations on clinical development data for DFP-10917 at the ASH 2026 Annual Meeting, Pursuing out-licensing negotiations and joint development with overseas pharmaceutical companies, focusing on pipelines under development |
Items this document does not state (18)
Net SalesGross Profit MarginOperating profit marginResults for the three months of the current quarterSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There was no business revenue, and business expenses consisted mainly of research and development expenses related to DFP-10917, DFP-14323 and DFP-17729. Research and development expenses decreased by ¥3 million, while general and administrative expenses decreased by ¥32 million.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.